NCT05272462 is a Phase 2 clinical trial of Minoxidil in Ovarian Cancer, sponsored by Loyola University.

Who is sponsoring NCT05272462?

NCT05272462 is sponsored by Loyola University.

What drugs are being tested in NCT05272462?

Interventions in NCT05272462: Minoxidil.

What condition does NCT05272462 study?

NCT05272462 studies Ovarian Cancer.

Is NCT05272462 still recruiting?

NCT05272462 is currently status unknown. Last updated 5 October 2023.

Last reviewed 2023-10-05 · How we verify

NCT05272462

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Oral Minoxidil for the Treatment of Recurrent Platinum Resistant Epithelial Ovarian Cancer

Status unknown Phase 2 Last updated 5 October 2023

What this trial tests

Phase 2 trial testing Minoxidil in Ovarian Cancer in 34 participants. Status unknown.

Timeline

13 December 2021

Primary endpoint
31 December 2024

31 December 2024

Quick facts

Lead sponsor	Loyola University
Phase	Phase 2
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	34
Start date	13 December 2021
Primary completion	31 December 2024
Estimated completion	31 December 2024
Sites	1 location across United States

Drugs / interventions tested

Minoxidil (minoxidil) — full drug profile →

Conditions studied

Ovarian Cancer — all drugs for Ovarian Cancer →

Sponsor

Loyola University

Who can join

Adults 18 to 90, female only, with Ovarian Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The primary purpose of this study is to determine the response rate of patients with recurrent platinum resistant ovarian cancer when treated with oral minoxidil. Secondary objectives include estimating the time to disease progression while on minoxidil and to describe the toxicities of minoxidil when used for patients with recurrent platinum resistant ovarian cancer. An exploratory objective is to evaluate if efficacy of minoxidil is improved in patients that have the Kir6/SUR complex versus those that do not.

Publications & conference data

5 peer-reviewed publications reference this trial (live from Europe PMC):

Drug Repurposing for Cancer Treatment: A Comprehensive Review.
Al Khzem AH, Gomaa MS, Alturki MS, Tawfeeq N, et al · · 2024 · cited 24× · PMID 39596504 · DOI 10.3390/ijms252212441
Overcoming the challenges of drug development in platinum-resistant ovarian cancer.
Eskander RN, Moore KN, Monk BJ, Herzog TJ, et al · · 2023 · cited 24× · PMID 37916177 · DOI 10.3389/fonc.2023.1258228
Targeting ion channels: innovative approaches to combat cancer drug resistance.
Shi Q, Yang Z, Yang H, Xu L, et al · · 2025 · cited 12× · PMID 39744692 · DOI 10.7150/thno.103384
In Vitro Drug Repurposing: Focus on Vasodilators.
Ribeiro E, Costa B, Vasques-Nóvoa F, Vale N. · · 2023 · cited 7× · PMID 36831338 · DOI 10.3390/cells12040671
Src and Abl as Therapeutic Targets in Lung Cancer: Opportunities for Drug Repurposing.
Ramos R, Sousa C, Vale N. · · 2025 · PMID 41155542 · DOI 10.3390/ph18101426

Verify or expand the search:

Other trials of Minoxidil

Trials testing the same drug.

NCT05864885 — Phase I Study of Safety and Pharmacokinetics of Topical Solution in Subjects With Androgenetic Alopecia · Phase 1 · unknown
NCT05990400 — Effectiveness and Safety of Topical Finasteride and Minoxidil Combination Compared to Topical Minoxidil for The Treatmen · Phase 2, PHASE3 · unknown
NCT05417308 — Topical or Oral Minoxidil for the Treatment of Endocrine Therapy-Induced Alopecia in Patients With Stage I-IV Breast Can · EARLY_PHASE1 · recruiting
NCT03528772 — Topical Minoxidil Versus Topical Glyceryl Trinitrate in Treatment of Chronic Anal Fissure · NA · completed

Other recruiting trials for Ovarian Cancer

Currently open trials in the same condition.

NCT06412120 — Study Evaluating Safety, Tolerability, and Metabolism of Niraparib · Phase 4 · recruiting
NCT06930755 — Study of NMS-03305293 in Adult Patients With Relapsed Ovarian Cancer · Phase 1 · recruiting
NCT07318558 — A Clinical Trial of Sac-TMT in People With Non-HRD Positive Advanced Ovarian Cancer (MK-2870-021) · Phase 3 · recruiting
NCT07491081 — EARLY Study: Evaluating the Specificity and Feasibility of the EARLY Biomarker Panel for Ovarian Cancer Detection · NA · recruiting
NCT07410676 — EBNK-001 Allogeneic NK Cells With Low-Dose IL-15 ± Pembrolizumab in Advanced Solid Tumors · Phase 1, PHASE2 · recruiting

Other Loyola University trials

Trials by the same sponsor.

NCT07517224 — Assessing the Effect of an Aerobic Exercise Program on Vascular Function in Women With Non-Metastatic Breast Cancer · NA · not yet recruiting
NCT06486714 — Mechanical Alignment Versus Kinematic Alignment Total Knee Arthroplasty · NA · not yet recruiting
NCT07216664 — Multisensory Early Oral Administration of Human Milk (M-MILK) for Very Preterm Infants · NA · recruiting
NCT07226505 — Effects of Core Strengthening Exercises for Treating TMD · NA · not yet recruiting
NCT06525701 — Surgeon Core-strengthening Program as a Modifier for Exertion Associated With Vaginal Surgery · NA · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05272462 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Loyola University
Last refreshed: 5 October 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05272462.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing